Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group.

The hepatocyte growth factor (HGF)-c-Met signaling axis is involved in the mediation of many biological activities, including angiogenesis, proliferation, cell survival, cell motility, and morphogenesis. Dysregulation of c-Met signaling (e.g., overexpression or increased activation) is associated with the proliferation and metastasis of a wide range of tumor types, including breast, liver, lung, colorectal, gastric, bladder, and prostate, among others. Inhibiting the HGF-c-Met pathway is predicted to lead to anti-tumor effects in many cancers. Elaboration of the SAR around a series of 2,4-diaminopyrimidines led to a number of c-Met inhibitors in which pharmaceutical properties were modulated by substituents appended on the C2-benzazepinone ring. In particular, certain-3-amidobenzazepin-2-one analogs had improved oral bioavailability and were evaluated in PK/PD and efficacy models. Lead compounds demonstrated tumor stasis with partial regressions when evaluated in a GTL-16 tumor xenograft mouse model.

[1]  P. Comoglio,et al.  Invasive growth: a MET-driven genetic programme for cancer and stem cells , 2006, Nature Reviews Cancer.

[2]  P. Scherle,et al.  Targeting the c-MET signaling pathway for cancer therapy , 2008 .

[3]  J. Armstrong,et al.  A convergent asymmetric synthesis of a growth hormone secretagogue , 2003 .

[4]  S. Tamura,et al.  Novel benzo-fused lactam scaffolds as factor Xa inhibitors. , 1999, Bioorganic & medicinal chemistry letters.

[5]  J. Christensen,et al.  A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase. , 2003, Cancer research.

[6]  K. Matsumoto,et al.  Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. , 2000, The Journal of clinical investigation.

[7]  J. Siegfried,et al.  Targeting of Both the c-Met and EGFR Pathways Results in Additive Inhibition of Lung Tumorigenesis in Transgenic Mice , 2010, Cancers.

[8]  J. E. Babiarz,et al.  Synthesis and biological properties of (carboxyalkyl)amino-substituted bicyclic lactam inhibitors of angiotensin converting enzyme. , 1985, Journal of medicinal chemistry.

[9]  A. Ullrich,et al.  SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high‐affinity binding site for SH2 domains of phospholipase C gamma. , 1992, The EMBO journal.

[10]  J. Porter.  Small molecule c-Met kinase inhibitors: a review of recent patents , 2010, Expert opinion on therapeutic patents.

[11]  S. Miknyoczki,et al.  Discovery of small molecule c-Met inhibitors: Evolution and profiles of clinical candidates. , 2010, Anti-cancer agents in medicinal chemistry.

[12]  S. Thorgeirsson,et al.  Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[13]  H. Staudinger,et al.  Über neue organische Phosphorverbindungen III. Phosphinmethylenderivate und Phosphinimine , 1919 .

[14]  M. Fisher,et al.  A novel 3-substituted benzazepinone growth hormone secretagogue (L-692,429). , 1994, Journal of medicinal chemistry.

[15]  J. Das,et al.  Benzazepinone calcium channel blockers. 4. Structure-activity overview and intracellular binding site. , 1992, Journal of medicinal chemistry.

[16]  Shinji Yamazaki,et al.  An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. , 2007, Cancer research.

[17]  L. Wodicka,et al.  A small molecule–kinase interaction map for clinical kinase inhibitors , 2005, Nature Biotechnology.

[18]  R. Stephens,et al.  Enzyme-linked immunosorbent assay for trkA tyrosine kinase activity. , 1996, Analytical biochemistry.

[19]  J. Ho,et al.  Novel, potent non-covalent thrombin inhibitors incorporating p(3)-lactam scaffolds. , 2002, Bioorganic & medicinal chemistry letters.

[20]  J. Christensen,et al.  A Selective c-Met Inhibitor Blocks an Autocrine Hepatocyte Growth Factor Growth Loop in ANBL-6 Cells and Prevents Migration and Adhesion of Myeloma Cells , 2004, Clinical Cancer Research.

[21]  M. Ishikawa,et al.  Synthesis and structure-activity relationships of dual histamine H2 and gastrin receptor antagonists with modified benzodiazepine skeletons. , 1997, Bioorganic & medicinal chemistry.

[22]  D. Hageman,et al.  5-Phenyl-3-ureidobenzazepin-2-ones as cholecystokinin-B receptor antagonists. , 1994, Journal of medicinal chemistry.

[23]  J. Christensen,et al.  A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. , 2003, Cancer research.

[24]  D. Macintyre,et al.  Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain. , 2007, Bioorganic & medicinal chemistry letters.

[25]  A. Jeng,et al.  Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme. , 1998, Journal of medicinal chemistry.

[26]  L. Schmidt,et al.  Activating mutations for the met tyrosine kinase receptor in human cancer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  G. V. Vande Woude,et al.  MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. , 2010, Cancer research.

[28]  K. L. Milkiewicz,et al.  Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors. , 2011, Bioorganic & medicinal chemistry letters.

[29]  P. Comoglio,et al.  Scatter factors and invasive growth. , 2001, Seminars in cancer biology.

[30]  L. Trusolino,et al.  Scatter-factor and semaphorin receptors: cell signalling for invasive growth , 2002, Nature Reviews Cancer.

[31]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[32]  D. Bottaro,et al.  Targeting the c-Met Signaling Pathway in Cancer , 2006, Clinical Cancer Research.

[33]  A. Howlett,et al.  Potent and selective inhibitors of the Met [hepatocyte growth factor/scatter factor (HGF/SF) receptor] tyrosine kinase block HGF/SF-induced tumor cell growth and invasion. , 2003, Molecular cancer therapeutics.